Success Metrics

Clinical Success Rate
81.3%

Based on 13 completed trials

Completion Rate
81%(13/16)
Active Trials
0(0%)
Results Posted
8%(1 trials)
Terminated
3(19%)

Phase Distribution

Ph phase_2
6
38%
Ph phase_1
10
63%

Phase Distribution

10

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
10(62.5%)
Phase 2Efficacy & side effects
6(37.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

81.3%

13 of 16 finished

Non-Completion Rate

18.8%

3 ended early

Currently Active

0

trials recruiting

Total Trials

16

all time

Status Distribution
Completed(13)
Terminated(3)

Detailed Status

Completed13
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
16
Active
0
Success Rate
81.3%
Most Advanced
Phase 2

Trials by Phase

Phase 110 (62.5%)
Phase 26 (37.5%)

Trials by Status

completed1381%
terminated319%

Recent Activity

0 active trials
Showing 5 of 16
completedphase_1

Safety of TKI258 in Advanced/Metastatic Melanoma Subjects

NCT00303251
completedphase_2

Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer

NCT01741116
completedphase_1

Phase I Dose Escalating Study of TKI258

NCT01471548
completedphase_1

Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors

NCT01421004
completedphase_1

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors

NCT01596647
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT00303251Phase 1

Safety of TKI258 in Advanced/Metastatic Melanoma Subjects

Completed
NCT01741116Phase 2

Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer

Completed
NCT01471548Phase 1

Phase I Dose Escalating Study of TKI258

Completed
NCT01421004Phase 1

Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors

Completed
NCT01596647Phase 1

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors

Completed
NCT00669097Phase 1

Absorption, Distribution, Metabolism and Excretion (ADME) Study of TKI258 in Patients With Advanced Solid Malignancies

Completed
NCT00715182Phase 1

A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer

Completed
NCT01155713Phase 1

Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors

Completed
NCT00958971Phase 2

Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer

Completed
NCT01058434Phase 2

Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation

Completed
NCT00790426Phase 2

Phase II Study of TKI258 in Advanced Urothelial Carcinoma

Completed
NCT01576380Phase 2

A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients

Completed
NCT02720926Phase 1

Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer

Terminated
NCT01379534Phase 2

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Completed
NCT00279773Phase 1

Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia

Terminated
NCT00243763Phase 1

TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma

Terminated

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16